Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C25H25N8O8PS.2Na |
| Molecular Weight | 674.533 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[Na+].CN1C=CC(=N1)S(=O)(=O)N2CCC[C@H](C2)NC3=NC=CC(=N3)C4=C(N=C5OC=CN45)C6=CC=CC(OCOP([O-])([O-])=O)=C6
InChI
InChIKey=HXINDCTZKGGRDE-JPKZNVRTSA-L
InChI=1S/C25H27N8O8PS.2Na/c1-31-11-8-21(30-31)43(37,38)32-10-3-5-18(15-32)27-24-26-9-7-20(28-24)23-22(29-25-33(23)12-13-39-25)17-4-2-6-19(14-17)40-16-41-42(34,35)36;;/h2,4,6-9,11-14,18H,3,5,10,15-16H2,1H3,(H,26,27,28)(H2,34,35,36);;/q;2*+1/p-2/t18-;;/m1../s1
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
300000041402
Created by
admin on Tue Apr 01 16:48:35 GMT 2025 , Edited by admin on Tue Apr 01 16:48:35 GMT 2025
|
PRIMARY | |||
|
1644503-82-1
Created by
admin on Tue Apr 01 16:48:35 GMT 2025 , Edited by admin on Tue Apr 01 16:48:35 GMT 2025
|
NO STRUCTURE GIVEN | |||
|
1228237-57-7
Created by
admin on Tue Apr 01 16:48:35 GMT 2025 , Edited by admin on Tue Apr 01 16:48:35 GMT 2025
|
PRIMARY | |||
|
46869123
Created by
admin on Tue Apr 01 16:48:35 GMT 2025 , Edited by admin on Tue Apr 01 16:48:35 GMT 2025
|
PRIMARY | |||
|
CHEMBL3545296
Created by
admin on Tue Apr 01 16:48:35 GMT 2025 , Edited by admin on Tue Apr 01 16:48:35 GMT 2025
|
PRIMARY | |||
|
C94224
Created by
admin on Tue Apr 01 16:48:35 GMT 2025 , Edited by admin on Tue Apr 01 16:48:35 GMT 2025
|
PRIMARY | BRAF inhibitor ARQ 736: An orally bioavailable, highly soluble phosphate prodrug of B-raf (BRAF) protein kinase with potential antineoplastic activity. BRAF inhibitor ARQ 736 is converted into its active form ARQ 680 in the presence of phosphatases. In turn, ARQ 680 selectively binds to and inhibits the activity of oncogenic B-raf, which may inhibit the proliferation of tumor cells expressing mutated B-raf gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations. The valine to glutamic acid substitution at residue 600 (V600E) accounts for about 90% of BRAF gene mutations. Check for active clinical trials using this agent. (NCI Thesaurus) | ||
|
Y2H4S74Y8U
Created by
admin on Tue Apr 01 16:48:35 GMT 2025 , Edited by admin on Tue Apr 01 16:48:35 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
